Reuters logo
BRIEF-Blueprint Medicines announces proof-of-concept data from Phase 1 clinical trial of BLU-285
2016年11月30日 / 晚上11点07分 / 10 个月前

BRIEF-Blueprint Medicines announces proof-of-concept data from Phase 1 clinical trial of BLU-285

Nov 30 (Reuters) - Blueprint Medicines Corp

* Blueprint Medicines announces proof-of-concept data from Phase 1 clinical trial of BLU-285 in patients with advanced gastrointestinal stromal tumors

* As of data cutoff date of November 1, 2016, BLU-285 was observed to be well-tolerated at all doses Source text for Eikon: Further company coverage:

我们的标准汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below